
5



- 1. An isolated p42 polypeptide expressed by an insect cell which contains a vector that encodes said polypeptide, wherein said polypeptide is more immunogenic in a manmalian host than is the same polypeptide expressed in yeast.
- 2. The polypeptide of Claim 1 further comprising a pharmaceutically acceptable carrier.
 - 3. The polypeptide of Claim 1, wherein the insect cell is selected from the group consisting of Spodoptera frugiperda, Spodoptera exiaua, Choristoneura fumiferana, Trichoplusia ni and Spodoptera littoralis.
 - 4. The polypeptide of Claim 1, wherein said polypeptide is a *Plasmodium falciparum* polypeptide.
 - 5. The polypeptide of Claim 4, wherein said *Plasmodium falciparum* polypeptide is an allelic form selected from the group consisting of MAD, K1, and Wellcome.
 - 6. The polypeptide of Claim 1, wherein the transmembrane domain of said polypeptide is deleted.
 - 7. The polypeptide of Claim 1, wherein said polypeptide is fused to a second polypeptide.
 - 8. The polypeptide of Claim 7, wherein said second polypeptide is a leader sequence fused to the amino terminus of said polypeptide.
- 9. The polypeptide of Claim 1 further comprising an adjuvant
 - 10. The polypeptide of Claim 9, wherein said adjuvant is selected from the group consisting of Freund's complete adjuvant, Freund's incomplete adjuvant, B30-MDP, LA-15-PH, saponin, aluminum hydroxide, MF59, MTP-PE, QS-21, ISA51 and combinations thereof.



- The polypeptide of Claim 1, wherein said vector is a baculovirus vector.
- 12. The polypeptide of Claim 1, wherein said mammalian host is a primate.
- 13. The polypeptide of Claim 1, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of:
 - (a) aming acids 1 to 394 of the amino acid sequence of SEQ ID NO:2;
 - (b) amino acids 1 to 394 of the amino acid sequence of SEQ ID NO:3;
 - (c) amino acids 1 to 377 of the amino acid sequence of SEQ ID NO:4;
 - (d) amino acids \(\) to 377 of the amino acid sequence of SEQ ID NO:5; and
 - (e) combinations thereof.
- 14. The polypeptide of Claim , wherein said polypeptide comprises an amino acid sequence selected from the group consisting of:
 - (a) amino acids 1 to 373 of the amino acid sequence of SEQ ID NO:2;
 - (b) amino acids 1 to 373 of the amino acid sequence of SEQ ID NO:3;
 - (c) amino acids 1 to 356 of the amino acid sequence of SEQ ID NO:4;
 - (d) amino acids 1 to 356 of the argino acid sequence of SEQ ID NO:5; and
 - (e) combinations thereof.
- 15. An anti-plasmodium immunogen comprising an immunogenic amount of an isolated p42 polypeptide expressed by an insect cell which contains a vector that encodes said polypeptide, wherein said polypeptide is more immunogenic in a mammalian host than is the same polypeptide expressed in yeast.
- 16. The immunogen of Claim 15 further comprising an adjuvant.
- 17. The immunogen Claim 16 wherein said adjuvant is selected from the group consisting of Freund's complete adjuvant, Freund's incomplete adjuvant, B30-MDP, LA-14-PH, saponin, aluminum hydroxide, MF59, MTP-PE, QS-21, ISA51, and combinations thereof.
- 18. The immunogen of Claim 15, wherein said polypeptide comprises an amino acid

20


5




sequence selected from the group consisting of:

- (a) amino acids 1 to 394 of the amino acid sequence of SEQ ID NO:2;
- (b)\ amino acids 1 to 394 of the amino acid sequence of SEQ ID NO:3;
- (c) \ amino acids 1 to 377 of the amino acid sequence of SEQ ID NO:4;
- (d) amino acids 1 to 377 of the amino acid sequence of SEQ ID NO:5; and
- (e) combinations thereof.
- 19. The immunoger of Claim 15, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of:
 - (a) amino acids \(\) to 373 of the amino acid sequence of SEQ ID NO:2;
 - (b) amino acids 1 to 373 of the amino acid sequence of SEQ ID NO:3;
 - (c) amino acids 1 to \$56 of the amino acid sequence of SEQ ID NO:4;
 - (d) amino acids 1 to 356 of the amino acid sequence of SEQ ID NO:5; and
 - (e) combinations thereof.
- 20. A method of inducing an anti-plasmodium immune response in a mammal comprising administering to said mammal the immunogen of Claim 15, 16, 17, 18, or 19.
- 21. The method of Claim 20, wherein said immune response substantially reduces plasmodium parasitemia in said mammal.
- 22. The method of Claim 20, wherein said mamma\(\) is a primate.
- 23. A method of producing a composition comprising a p42 polypeptide, wherein said polypeptide is more immunogenic in a mammalian host than is the same polypeptide expressed in yeast comprising, causing an insect cell which contains a vector that encodes said polypeptide to express said polypeptide.
 - 24. The method of Claim 23 further comprising purifying said polypeptide.
- 25. The method of Claim 23, wherein the insect cell is selected from the group consisting of Spodoptera frugiperda, Spodoptera exiaua, Choristoneura fumiferana,

5



- 26. The method of Claim 23, wherein said polypeptide is a *Plasmodium falciparum* polypeptide.
- 27. The method of Claim 26, wherein said *Plasmodium falciparum* polypeptide is an allelic form selected from the group consisting of MAD, K1, and Wellcome.
- 28. The method of Chaim 23, wherein the transmembrane domain of said polypeptide is deleted.
- 29. The method of Claim 23, wherein said polypeptide is fused to a second polypeptide.
- 30. The method of Claim 29, wherein said second polypeptide is a leader sequence.
- 31. The method of Claim 23, further comprising adding an adjuvant to said polypeptide.
- 32. The method of claim 31, where said adjuvant is selected from the group consisting of Freund's complete adjuvant, Freund's incomplete adjuvant, B30-MDP, LA-15-PH, saponin, aluminum hydroxide, MF59, MTP-PE, QS-21, ISA51 and combinations thereof.
- 15 33. The method of Claim 23, wherein said vector is a baculovirus vector.
 - 34. The method of Claim 23, wherein said mammalian host is a primate.
 - 35. The method of Claim 23, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of:
 - (a) amino acids 1 to 394 of the amino acid sequence of SEQ ID NO:2;
 - (b) amino acids 1 to 394 of the amino acid sequence of SEQ ID NO:3;
 - (c) amino acids 1 to 377 of the amino acid sequence of SEQ ID NO:4;
 - (d) amino acids 1 to 377 of the amino acid sequence of SEQ ID NO:5; and



ò

- 36. The method of Claim 23, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of:
 - (a) amino acids 1 to 373 of the amino acid sequence of SEQ ID NO:2;
 - (b) amino acids 1 to 373 of the amino acid sequence of SEQ ID NO:3;
 - (c) amino acids 1 to 356 of the amino acid sequence of SEQ ID NO:4;
 - (d) amino acids 1 to 356 of the amino acid sequence of SEQ ID NO:5; and
 - (e) combinations thereof.

